Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Bromodeoxyuridine Ç¥Áö¿¡ ÀÇÇÑ ÀÎü »óÇÇ ¼¼Æ÷¾ÏÀÇ ¼¼Æ÷ ¿ªµ¿ÇÐ ¿¬±¸ Cell Kinetics Studies of Human Epithelial Cancers with Bromodeoxyuridine Labeling

´ëÇѾÏÇÐȸÁö 1995³â 27±Ç 5È£ p.783 ~ 789
¼Ò¼Ó »ó¼¼Á¤º¸
¼ºÁø½Ç ÀÌÁ¤¿î/Á¤ÀºÁö/±è¿µÅÂ/±èÀç¿í/±è³²±Ô/È«¼ºÁØ/ÃÖÀºÃ¢/ÀÌ¿ø»ó

Abstract


Cell kinetic parameters of labeling index (LI), duration of S-phase (Ts), and potential doubling time (Tpot) were analyzed following infusion of bromodeoxyuridine (BUdR) in 33 patients with various epithelial cancers. Twelve uterine cervical
cancers, 9
rectal cancers, 7 head and neck cancers, and 5 bladder cancers were included. Biopsies were taken about 4~6 h after 200mg/m* BUdR infusion and the samples were analyzed with bivariate DNA/BUdR flow cytometry.
The distribution of cell kinetic parameters for the 33 epithelial cancers showed a large range of values for each parameter. The median LI, Ts, and Tpot were 4.5%. 10.8 h, and 242.3 h, respectively. Eight among 33 patients (24.2%) showed
aneuploidy. In
aneuploid tumors the distribution of LI, Ts, and Tpot was in relatively small range. Aneupliod tumors appeared to show higher LI and shorter Tpot than those in diploid tumors. In diploid tumors, the possibility of normal cell contamination could
not be
ruled out.
The results of this study would be a basis for future trial to predict which ones would show tumor clonogen repopulation during radiotherapy so that benefit from altered fractionated radiotherapy.

Å°¿öµå

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS